ACCESSIBILITY

24/7

Headlines

08:42

AI sparked a global arms race among tech giants for electric reserves—can we maintain energy independence?

08:42

Exodigo’s journey from underground to one of Israel’s most promising startups

08:42

How Greenfield Partners identified one of Calcalist’s 'Most Promising Startups'

15:16

Joonko files for Chapter 11, plans to distribute remaining $4.25 million to investors

Buzz

Most popular

Daily

Weekly

Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale

The 50 most promising Israeli startups - 2024

Glassbox to be taken private by Alicorn VC in $150 million deal

“GenAI creates an attack surface different from everything we've seen before”

Blackstone acquires Israel’s Priority Software at an $800 million valuation

More news

Pharmaceuticals

15 stories about Pharmaceuticals

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer

Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer

According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.

מימין עודד ליברמן מנכל נוירודרם עם נציגי הרוכשת מיצובישי טנאבה

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm

19.10.17|Lilach Baumer

NeuroDerm is looking to bring major change to Parkinson patients with its drug reformulation

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

Lonza to Open Research and Development Center in Israel

10.10.17|Lilach Baumer

The company is looking to boost the research and development projects of its pharma and biotech division

Drug Conduction Company Prepares for Nasdaq IPO

08.10.17|Golan Hazani

Clinical stage PolyPid develops technology for the predetermined, controlled and localized release of drugs at a targeted site

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Pharma Companies Arcturus Therapeutics and Alcobra to Merge

28.09.17|Lilach Baumer

The merged entity will develop treatments for infectious diseases, cystic fibrosis, and rare liver diseases

Automated Medical Diagnosis Startup Raises $30 Million

19.09.17|Omer Kabir

Israel-based MeMed develops an automated blood testing device that can distinguish between bacterial and viral infections. The company previously raised funds from the U.S. Department of Defense

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich

Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated